Výsledky vyhledávání - "Daniel E.H. Afar"

Supplementary Data from Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma

Autor: Daniel E.H. Afar, Shmuel Yaccoby, Bart Barlogie, John D. Shaughnessy, Fenghuang Zhan, Audie G. Rice, Debra Chao, Bishwa Ganguly, Balaji Balasa, Rui Yun, Amberly M. Moreno-Bost, JuMei Shi, Tarun K. Garg, Mary K. Stone, Xin Li, Anne M. van Abbema, Myles Dillon, Susann M. Szmania, Frits van Rhee

Supplementary Data from Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22ceb3c738108976650d682599b1dbd3
https://doi.org/10.1158/1535-7163.22486031

Zobrazit plný text záznamu

Table S1 from First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma

Autor: Philippe Moreau, Jesús F. San-Miguel, Anil Singhal, Bruno Paiva, Anita Reddy, James P. Sheridan, Scott Gulbranson, Shekman Wong, Katja Weisel, Xavier Leleu, Andrzej J. Jakubowiak, Joaquín Martínez-López, Andreas Guenther, Marc S. Raab, Jesús G. Berdeja, María-Victoria Mateos, Daniel E.H. Afar, Rajneesh Nath, Ravi Vij

Overall summary of treatment-emergent adverse events

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::072e401dc2fdc93db09c050b8ac6354a
https://doi.org/10.1158/1078-0432.22471553.v1

Zobrazit plný text záznamu

Data from First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma

Purpose:ABBV-838 is an antibody–drug conjugate targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells. This phase I/Ib first-in-human, dose-escalation study (trial registration ID: NCT02462525) e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b92335383f066e12e00748e447cf92c
https://doi.org/10.1158/1078-0432.c.6527927.v1

Zobrazit plný text záznamu

Figure S1 from First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma

Study design schematic. N, number of patients in each dose group; PK/PD, pharmacokinetics/pharmacodynamics.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b8ad54bf2863964b9eb23f6cb05576d
https://doi.org/10.1158/1078-0432.22471556

Zobrazit plný text záznamu

Data from Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma

Monoclonal antibody (mAb) therapy for multiple myeloma, a malignancy of plasma cells, has not been clinically efficacious in part due to a lack of appropriate targets. We recently reported that the cell surface glycoprotein CS1 (CD2 subset 1, CRACC,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ef3d3e9283c21d752107367ae7e8ce8
https://doi.org/10.1158/1535-7163.c.6532202

Zobrazit plný text záznamu

Recognition of multiple substrate motifs by the c-ABL protein tyrosine kinase

Autor: Jinzi J. Wu, Daniel E.H. Afar, Owen N. Witte, Kit S. Lam, Hoang Phan

Publikováno v: Combinatorial chemistryhigh throughput screening. 5(1)

Using a combinatorial peptide library that is based on the one-bead one-peptide approach we identified 14 peptide substrates for the c-ABL protein tyrosine kinase, which define three distinct consensus sequence groups. This is distinct from many seri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02e4ad638b9e4cbb3f8757820bdd5eaf
https://pubmed.ncbi.nlm.nih.gov/11860343

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání